

Novartis Pharmaceuticals Corporation

VT S.92 (Act 193, Sec.10.18 V.S.A Â§ 4637) Reporting

Overview

In Accordance with the requirements of subsection B set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A Â§ 4637) regulation, this is our 30-day post launch report of the introduction of the products listed below, into the state of Vermont.

The Product(s)

FABHALTA HGC 200MG 60

Marketing Plans

The marketing for FABHALTA includes education and promotion to physicians, direct to consumer promotions, other types of marketing (e.g., online platforms and education).

Pricing Plans

Branded Name	Generic Name	NDC	WAC Package Price	Effective Date
FABHALTA	Iptacopan	00078-1189-20	\$45205.48	12/08/2023

Novartis considered many factors in determining the price of Fabhalta (Iptacopan). Fabhalta is an efficacious treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH) and the first and only oral monotherapy to become available for patients. Fabhalta, now available for both previously treated and treatment-naive patients, is the only FDA-approved Factor B inhibitor of the immune system's complement pathway, which drives complement-mediated hemolysis in PNH. The price for FABHALTA reflects the benefits it may provide people living with PNH and also considers the overall value FABHALTA may provide to the healthcare system compared to currently available therapies. The branded therapies used for reference were Ultomiris and Soliris from Alexion and Empaveli from Apellis.

Estimated Volume of Patients

7000

Breakthrough Designation

Yes

Date of Acquisition

The date of acquisition of the product(s) is listed below.

NDC	Date of Acquisition
00078-1189-20	N/A